Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Conditions: Gastric Cancer; MSI-H; Metastatic Cancer; Advanced Cancer Interventions: Drug: Balstilimab; Drug: Botensilimab; Drug: Folfox Protocol; Drug: XELOX; Drug: Nivolumab Sponsors: Centre Leon Berard; Agenus Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials